Unoje, O, Hussain, Y, Habib, A, Claeys, K, Gwathmey, K, Sahagian, G, Cortés-Vicente, E, Liu, L, Jimenez, R, Patel, M, Masschaele, D, Mantegazza, R, Meisel, A, Seth, A, Attarian, S. Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. ANNALS OF NEUROLOGY. 2025; 98DOI:. PMID:. IF:7.700(Q1/1D).

Sánchez-Aced, E, Moya-Llamas, B, Escabias, JA, Torres, S, Colom-Cadena, M, Pegueroles, J, de Quintana-Schmidt, C, Bayes, A, Molina-Porcel, L, Aldecoa, I, Belbin, O, Fortea, J, Spires-Jones, T, Pujals, S, Sirisi, S, Lleo, A. Enhancing Lateral Resolution Using Two-Colour Direct Stochastic Optical Reconstruction Microscopy to Unravel Synaptic Tau Pathology in Alzheimer's Disease. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY. 2025; 51(2)DOI:10.1111/nan.70010. PMID:40025904. IF:3.400(Q1/3D).

Martín-Aguilar, L, Querol, L. Reply to "Letter to the Editor: Pitfalls in Calculating the Incidence of GBS During the Pandemic". EUROPEAN JOURNAL OF NEUROLOGY. 2025; 32(2)DOI:10.1111/ene.70069. PMID:39931912. IF:3.900(Q1/3D).

Neal, MA, Bolano-Diaz, CF, Richardson, M, Michell-Sodhi, J, Muni-Lofra, R, James, MK, Hollingsworth, KG, Hilsden, H, Wilson, I, Blamire, AM, Straub, V, Thelwall, PE, Diaz-Manera, J. Rapid Quantitative Assessment of Muscle Sodium Dynamics After Exercise Using 23Na-MRI in Dysferlinopathy and Healthy Controls. Journal of Cachexia Sarcopenia and Muscle. 2025; 16(1)DOI:10.1002/jcsm.13709. PMID:39900102. IF:9.100(Q1/1D).

Dominguez-González, C, Iannucci, D, Clark, J, Martin-Jiménez, P, Hold, S, Oliva, P, Bischinger, A, Gallardo, E, Diaz-Manera, J. Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 60DOI:10.1016/j.nmd.2026.106359. PMID:41638029. IF:2.800(Q2/5D).

Vesperinas, A, Rocaspana-Codana, J, Reyes-Leiva, D, Caballero-Avila, M, Carbayo, A, Collet-Vidiella, R, Llanso, L, Gallardo, E, Turon-Sans, J, Rojas-Garcia, R, Cortes-Vicente, E. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. NEUROMUSCULAR DISORDERS. 2026; 59DOI:10.1016/j.nmd.2025.106284. PMID:41442860. IF:2.800(Q2/5D).

Schirinzi, E, Bochicchio, MA, Lochmüller, H, Vissing, J, Jordie-Diaz-Manerae, Evangelista, T, Plançon, JP, Fanucci, L, Marini, M, Tonacci, A, Mancuso, M, Segovia-Kueny, S, Toscano, A, Angelini, C, Schoser, B, Sacconi, S, Siciliano, G, e-NMD Grp. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders. Journal Of Neuromuscular Diseases. 2026; 13(1)DOI:10.3233/JND-230091. PMID:38728200. IF:3.400(Q2/3D).

Allen, JA, Querol, L, Suresh, N, Remmerie, A, Mole, T, McCoy, K, Butler, L, van Hoorick, B, Kuwabara, S, van Doorn, PA, Lewis, RA. Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial. Therapeutic Advances in Neurological Disorders. 2026; 19DOI:10.1177/17562864251405202. PMID:41583073. IF:4.100(Q1/2D).

Armangué, T, Gómez-Ballesteros, R, Querol, L, Gutiérrez-Gutiérrez, G, Sotoca, J, Luque, AA, Villaverde, R, Reyes, V, Salas, E, Diaz, P, Maurino, J, Cortés-Vicente, E. ORGANIZATIONAL SUPPORT IN ADOPTING NEW TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).

Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).

Cegarra, PL, Caballero-Avila, M, De Lorenzo, A, Lleixà, C, Collet-Vidiella, R, Martín-Aguilar, L, Pascual-Goñi, E, Querol, L. Absence of Anti-LGI4 Autoantibodies in a European Cohort of CIPD Patients. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Collet-Vidiella, R, Caballero-Avila, M, Llarch, P, Tejada-Illa, C, Pascual-Goñi, E, Martín-Aguilar, L, Lleixà, C, Vesperinas, A, Carbayo-Viejo, A, Llansó, L, Rojas, R, Querol, L. CIDP With Anti-GM1 IgM Antibodies: A Continuum With Multifocal Motor Neuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Illa, CT, Pegueroles, J, Claramunt-Molet, M, Pi-Cervera, A, Heras-Delgado, A, Gascón-Fontal, J, Idelsohn-Zielonka, S, Rico, M, Vidal, N, Martín-Aguilar, L, Caballero-Avila, M, Lleixà, C, Collet-Vidiella, R, Llarch, P, Llansó, L, Carbayo-Viejo, A, Vesperinas, A, Querol, L, Pascual-Goñi, E. Balance Assessment in Patients With Peripheral Neuropathies Using Digital Biomechanical Biomarkers. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Hourcade, S, Chow, T, Chen, Y, Levit, M, Hammond, TR, Kramer, ML, Ternes, N, Seluzhytsky, A, Alonso-Alonso, M, Atassi, N, Lewis, RA. Exploratory Biomarker Analyses in a Phase 2 Trial of Riliprubart for Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Allen, J, Lin, J, Stettner, M, Guptill, J, Istas, G, De Roeck, A, Kuwabara, S, Pinter, GL, Querol, L, Suresh, N, Karam, C, Skripuletz, T, Rinaldi, S, Echaniz-Laguna, A, Hewamadduma, C, Van Hoorick, B, Yamasaki, R, Van Doorn, PA, Lewis, RA. ADHERE plus Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Lewis, RA, Hartung, HP, van Doorn, PA, Lin, J, Dionne, A, Attarian, S, Wallstroem, E, Auwarter, K, Lu, Y, Alonso, MA, Atassi, N, Hughes, RAC. Safety and Efficacy of Riliprubart in CIDP: 76-Week Phase 2 Trial Results. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Querol, L, Harbo, T, Peric, S, Hussain, Y, Cadour, S, Van de Walle, I, Persson, E, Vujcic, M, Van de Steen, O, Allen, J, Nobile-Orazio, E, Attarian, S, Karam, C, Katzberg, H, Stettner, M, Rinaldi, S, van der Pol, WL. Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Hewamadduma, C, Peric, S, Claeys, K, Querol, L, Altamimi, S, Van de Walle, I, Persson, E, Van Hoomissen, I, Szmyd, G, Vujcic, M, Cadour, S, Van de Steen, O, Arvin-Berod, C, Allen, J. Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Falzone, Y, Sommer, C, Querol, L, Allen, J, Merkies, I, Van Doorn, P, Wallstroem, E, Lu, Y, Alonso-Alonso, M, Atassi, N, Lewis, RA. Riliprubart Phase 3 MOBILIZE and VITALIZE Trials for CIDP are Actively Enrolling Globally. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).

Stettner, M, Allen, J, Rinaldi, S, Pinter, GL, Querol, L, Magy, L, De Roeck, A, Van Hoorick, B, Hofman, E, Istas, G, Skripuletz, T, Lewis, R, Van Doorn, PA. Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive/Relapsing Active Disease: ADHERE Analysis. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM. 2025; 30(3)DOI:. PMID:. IF:3.200(Q2/4D).